^
Association details:
| Biomarker: | BRAF mutation |
|---|---|
| Cancer: | Thyroid Gland Papillary Carcinoma |
| Drug: | plixorafenib (FORE-8394) (BRAF inhibitor, BRAF V600E inhibitor) + Tybost (cobicistat) (Cytochrome P450 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Interim results from a phase 1/2 precision medicine study of PLX8394- a next generation BRAF inhibitor
Published date:
10/25/2020
Excerpt:
Of 45 evaluable pts with BRAF-mutations...10 pts (22%) achieved confirmed and mostly durable partial responses (gliomas (3), ovarian (2), and 1 each for papillary thyroid cancer, small bowel, colorectal carcinoma, anaplastic thyroid carcinoma, and melanoma).
Trial ID:
